Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen Licenses Metabolic Drug from Hanmi Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen Licenses Metabolic Drug from Hanmi Pharma

To develop and commercialize HM12525A in metabolic diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Janssen Pharmaceuticals, Inc. has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies from Hanmi Pharmaceutical Co. The agreement includes HM12525A, a biologic expected to enter Phase II studies next year.
 
HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has been shown to improve multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity, as a once weekly therapy.
 
“We are very excited about this agreement with Hanmi and the potential of HM12525A to improve therapeutic options for people living with metabolic diseases,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen. “Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases. We look forward to developing this potential best-in-class therapy, which allows us to build on our success in diabetes and strengthen our metabolism portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics